Aurobindo Pharma gets USFDA nod for Meropenem injection

By: | Published: March 28, 2017 12:37 PM

Drug firm Aurobindo Pharma has received final approval from the US health regulator for Meropenem injection used for treatment of complicated skin and related infections, complicated intra abdominal infections and bacterial meningitis.

The company “has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Meropenem injection 500 mg/vial and 1g/ vial,” Aurobindo Pharma said in a filing to BSE. (Reuters)

Drug firm Aurobindo Pharma has received final approval from the US health regulator for Meropenem injection used for treatment of complicated skin and related infections, complicated intra abdominal infections and bacterial meningitis. The company “has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Meropenem injection 500 mg/vial and 1g/ vial,” Aurobindo Pharma said in a filing to BSE.

This is a generic version of AstraZeneca Pharmaceuticals’ Merrem injection, it added. “The approved product has an estimated market size of $118 million for the 12-month ending January 2017, according to IMS,” said Aurobindo Pharma.

Watch this also:

This is the first ANDA (Abbreviated New Drug Application) approved out of Auronext Pharma facility in Bhaiwadi used for manufacturing penem injectable products. Auronext Pharma is a wholly-owned subsidiary of Aurobindo Pharma. With this, Aurobindo now has a total of 314 ANDA approvals.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition